Back to news

Nexentis: MitoCareX Progresses Toward In-Vitro Evaluation Following AI-Powered Computational Screening

Globe Newswire•17/11/2026•08:03 ET
0

Key Highlights

  • ➤MitoCareX selected and ordered molecules for planned in-vitro evaluation
  • ➤Molecules have not been received; in-vitro testing has not begun
  • ➤AI-generated computational predictions remain experimentally unvalidated
  • ➤Boltz collaboration combines AI models with MitoCareX drug-discovery capabilities

Further computational prioritization by MitoCareX leads to selection and ordering of molecules for planned experimental assessment

Ness Ziona, Israel, , Nov. 17, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”) today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX”), has selected and ordered molecules for planned in-vitro evaluation following further computational prioritization of preliminary findings from its previously announced screening work. This represents a next research step toward experimental assessment of selected molecules.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in